A rogue pharmaceutical company ramped up the cost of a common antibiotic by 400 percent. While the medical community is irate, could high prices make antibiotics worth investing in?
The Case for Expensive Antibiotics
A rogue pharmaceutical company ramped up the cost of a common antibiotic by 400 percent. While the medical community is irate, could high prices make antibiotics worth investing in?
